UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D. C. 20549

_______________________________________________________

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant~~ toApril ~~Section~~10, ~~13 or 15(d) of the~~2026

Securities Exchange Act of 1934

April 16, 2026

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

_______________________________________________________

Illinois	1-2189	36-0698440
(State or other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

Illinois

1-2189

36-0698440

(State or other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

_______________________________________________________

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class ~~TradingSymbol~~Trading Symbol(s) Name of Each ~~Exchangeon~~Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock ~~ExchangeNYSE~~Exchange NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ¨

Item 28.~~02 Results~~01 ofOther ~~Operations and Financial Condition~~Events.

OnAs ~~April~~previously disclosed in Abbott’s Annual Reports on Form 1610-K for the fiscal years ended December 31, ~~2026~~2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories ~~announced~~Infant ~~its~~Formula ~~results~~Shareholder ofDerivative ~~operations~~Litigation, before the United States District Court for the ~~first~~Northern ~~quarter~~District of Illinois against certain of Abbott’s current and former directors and officers. On April 10, 2026, in connection with that consolidated proceeding, the court signed an “Order Preliminarily Approving Proposed Settlement, Directing The Issuance Of Notice, And Setting A Final Settlement Hearing.”

~~Furnished~~A ascopy Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of ~~a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of~~ the ~~resolution~~Notice of ~~various~~Proposed ~~tax~~Settlement positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of ~~operations~~Consolidated ~~excluding these costs~~Derivative Action, ~~similar~~Final toSettlement how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. AbbottHearing, ~~however,~~and ~~cautions~~Right ~~investors~~ to ~~consider~~Appear ~~these~~is ~~non-GAAP~~filed ~~financial measures in addition to, and not~~ as ~~a substitute for, financial measures prepared in accordance with GAAP~~Exhibit 99. 1.

Item 9.01 Financial Statements and Exhibits.

~~Exhibit No.~~	Exhibit No.	Exhibit	~~Exhibit~~
~~99.1~~	99.1	Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear.	~~Press Release dated April 16, 2026 (furnished pursuant to Item 2.02).~~
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABBOTT LABORATORIES		~~ABBOTT LABORATORIES~~
Date: April 16, 2026			By:	/s/ Philip P. Boudreau
Date: April 17, 2026	By:	/s/ Philip P. Boudreau
		Philip P. Boudreau		~~Philip P. Boudreau~~
		Executive Vice President, Finance and Chief Financial Officer		~~Executive Vice President, Finance and Chief Financial Officer~~

Filing Compare · ABBOTT LABORATORIES